Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 1997, 185:111-120.
Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
Kollet O., Spiegel A., Peled A., Petit I., Byk T., Hershkoviz R., Guetta E., Barkai G., Nagler A., Lapidot T. Rapid and efficient homing of human CD34+CD38-/lowCXCR4+ stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2mnull mice. Blood 2001, 97:3283-3291.
Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., Yoshida N., Kikutani H., Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393:591-594.
Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4:540-550.
Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
Hernandez P.A., Gorlin R.J., Lukens J.N., Taniuchi S., Bohinjec J., Francois F., Klotman M.E., Diaz G.A. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 2003, 34:70-74.
Zlotnik A. Chemokines and cancer. Int. J. Cancer 2006, 119:2026-2029.
Richman D.D., Bozzette S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 1994, 169:968-974.
Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., Wu L., Mackay C.R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
Berger E.A. HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11(Suppl. A):S3-S16.
Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., Weiss R.A. A new classification for HIV-1. Nature 1998, 391:240.
Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17:657-700.
Davenport M.P., Zaunders J.J., Hazenberg M.D., Schuitemaker H., van Rij R.P. Cell turnover and cell tropism in HIV-1 infection. Trends in microbiology 2002, 10:275-278.
Ribeiro R.M., Hazenberg M.D., Perelson A.S., Davenport M.P. Naive and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J. Virol. 2006, 80:802-809.
Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
Picker L.J. Immunopathogenesis of acute AIDS virus infection. Curr. Opin. Immunol. 2006, 18:399-405.
Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 2006, 12:289-295.
Groot F., van Capel T.M., Schuitemaker J., Berkhout B., de Jong E.C. Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 2006, 3:52.
Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14:171-179.
Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 2010, 16:2927-2931.
Marchesi F., Monti P., Leone B.E., Zerbi A., Vecchi A., Piemonti L., Mantovani A., Allavena P. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004, 64:8420-8427.
Kledal T.N., Rosenkilde M.M., Coulin F., Simmons G., Johnsen A.H., Alouani S., Power C.A., Luttichau H.R., Gerstoft J., Clapham P.R., Clark-Lewis I., Wells T.N., Schwartz T.W. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997, 277:1656-1659.
Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., Arenzana-Seisdedos F., Thelen M., Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 2005, 280:35760-35766.
Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., Taichman R.S., Pienta K.J., Wang J. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2011, 29:269-270.
Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., Kleer C.G., Essner J.J., Nasevicius A., Luker G.D., Howard M.C., Schall T.J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15735-15740.
Grymula K., Tarnowski M., Wysoczynski M., Drukala J., Barr F.G., Ratajczak J., Kucia M., Ratajczak M.Z. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int. J. Cancer 2010, 2554-2568.
Sanchez-Martin L., Sanchez-Mateos P., Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol. Med. 2012, 12-22.
Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., Hamel D.J., Kuhn P., Handel T.M., Cherezov V., Stevens R.C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
Brelot A., Heveker N., Montes M., Alizon M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J. Biol. Chem. 2000, 275:23736-23744.
Doranz B.J., Orsini M.J., Turner J.D., Hoffman T.L., Berson J.F., Hoxie J.A., Peiper S.C., Brass L.F., Doms R.W. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J. Virol. 1999, 73:2752-2761.
Zhou N., Luo Z., Luo J., Liu D., Hall J.W., Pomerantz R.J., Huang Z. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J. Biol. Chem. 2001, 276:42826-42833.
Fernandez E.J., Lolis E. Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 2002, 42:469-499.
Allen S.J., Crown S.E., Handel T.M. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 2007, 25:787-820.
Crump M.P., Gong J.H., Loetscher P., Rajarathnam K., Amara A., Arenzana-Seisdedos F., Virelizier J.L., Baggiolini M., Sykes B.D., Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997, 16:6996-7007.
Monteclaro F.S., Charo I.F. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. 1996, 271:19084-19092.
Veldkamp C.T., Seibert C., Peterson F.C., De la Cruz N.B., Haugner J.C., Basnet H., Sakmar T.P., Volkman B.F. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal. 2008, 1:1160755.
Gozansky E.K., Louis J.M., Caffrey M., Clore G.M. Mapping the binding of the N-terminal extracellular tail of the CXCR4 receptor to stromal cell-derived factor-1alpha. J. Mol. Biol. 2005, 345:651-658.
Heveker N., Montes M., Germeroth L., Amara A., Trautmann A., Alizon M., Schneider-Mergener J. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr. Biol. 1998, 8:369-376.
Loetscher P., Gong J.H., Dewald B., Baggiolini M., Clark-Lewis I. N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J. Biol. Chem. 1998, 273:22279-22283.
Zhou N., Luo Z., Luo J., Hall J.W., Huang Z. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry 2000, 39:3782-3787.
Chevigne A., Fievez V., Schmit J.C., Deroo S. Engineering and screening the N-terminus of chemokines for drug discovery. Biochem. Pharmacol. 2011, 82:1438-1456.
Kofuku Y., Yoshiura C., Ueda T., Terasawa H., Hirai T., Tominaga S., Hirose M., Maeda Y., Takahashi H., Terashima Y., Matsushima K., Shimada I. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J. Biol. Chem. 2009, 284:35240-35250.
Gerlach L.O., Skerlj R.T., Bridger G.J., Schwartz T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001, 276:14153-14160.
Tamamura H., Hori A., Kanzaki N., Hiramatsu K., Mizumoto M., Nakashima H., Yamamoto N., Otaka A., Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003, 550:79-83.
Tsutsumi H., Tanaka T., Ohashi N., Masuno H., Tamamura H., Hiramatsu K., Araki T., Ueda S., Oishi S., Fujii N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers 2007, 88:279-289.
Heveker N., Tissot M., Thuret A., Schneider-Mergener J., Alizon M., Roch M., Marullo S. Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells. Mol. Pharmacol. 2001, 59:1418-1425.
Huang E.H., Singh B., Cristofanilli M., Gelovani J., Wei C., Vincent L., Cook K.R., Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res. 2009, 155:231-236.
Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 2009, 75:1240-1247.
Zhang W.B., Navenot J.M., Haribabu B., Tamamura H., Hiramatu K., Omagari A., Pei G., Manfredi J.P., Fujii N., Broach J.R., Peiper S.C. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem. 2002, 277:24515-24521.
Galzi J.L., Hachet-Haas M., Bonnet D., Daubeuf F., Lecat S., Hibert M., Haiech J., Frossard N. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol. Ther. 2010, 126:39-55.
Boussard C., Klimkait T., Mahmood N., Pritchard M., Gilbert I.H. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions. Bioorg. Med. Chem. Lett. 2004, 14:2673-2676.
Veldkamp C.T., Ziarek J.J., Peterson F.C., Chen Y., Volkman B.F. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J. Am. Chem. Soc. 2010, 132:7242-7243.
Hachet-Haas M., Balabanian K., Rohmer F., Pons F., Franchet C., Lecat S., Chow K.Y., Dagher R., Gizzi P., Didier B., Lagane B., Kellenberger E., Bonnet D., Baleux F., Haiech J., Parmentier M., Frossard N., Arenzana-Seisdedos F., Hibert M., Galzi J.L. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J. Biol. Chem. 2008, 283:23189-23199.
Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9770-9774.
Zhong C., Wang J., Li B., Xiang H., Ultsch M., Coons M., Wong T., Chiang N.Y., Clark S., Clark R., Quintana L., Gribling P., Suto E., Barck K., Corpuz R., Yao J., Takkar R., Lee W.P., Damico-Beyer L., Carano R.A., Adams C., Kelley R., Wang W., Ferrara N. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin. Cancer Res. 2013, 4433-4445.
Blanchetot C., Verzijl D., Mujic-Delic A., Bosch L., Rem L., Leurs R., Verrips C.T., Saunders M., de Haard H., Smit M.J. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J. Biol. Chem. 2013, 288:25173-25182.
Szpakowska M., Fievez V., Arumugan K., van Nuland N., Schmit J.C., Chevigne A. Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. Biochem. Pharmacol. 2012, 84:1366-1380.
Duda D.G., Kozin S., Kirkpatrick N.D., Xu L., Fukumura D., Jain R.K. CXCL12 (SDF1α) - CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anti-cancer therapies?. Clin. Cancer Res. 2011, 2074-2080.
Deroo S., Fischer A., Beaupain N., Counson M., Boutonnet N., Pletinckx J., Loverix S., Beirnaert E., De Haard H., Schmit J.C., Lasters I. Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope. Mol. Immunol. 2008, 45:1366-1373.
Trkola A., Matthews J., Gordon C., Ketas T., Moore J.P. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 1999, 73:8966-8974.
Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985, 229:563-566.
Ahuja S.K., Lee J.C., Murphy P.M. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J. Biol. Chem. 1996, 271:225-232.
Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20:309-321.
Pauwels R., De Clercq E., Desmyter J., Balzarini J., Goubau P., Herdewijn P., Vanderhaeghe H., Vandeputte M. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Methods 1987, 16:171-185.
Mulinge M., Lemaire M., Servais J.Y., Rybicki A., Struck D., da Silva E.S., Verhofstede C., Lie Y., Seguin-Devaux C., Schmit J.C., Bercoff D.P. HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRRF01_AE and CRF02_AG. PLoS One 2013, 8:e60566.
Baatz F., Nijhuis M., Lemaire M., Riedijk M., Wensing A.M., Servais J.Y., van Ham P.M., Hoepelman A.I., Koopmans P.P., Sprenger H.G., Devaux C., Schmit J.C., Perez Bercoff D. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates. PLoS One 2011, 6:e21535.
Perez-Bercoff D., Wurtzer S., Compain S., Benech H., Clavel F. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J. Virol. 2007, 81:4540-4550.
Myszka D.G. Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzymol. 2000, 323:325-340.
Agrawal L., VanHorn-Ali Z., Berger E.A., Alkhatib G. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004, 103:1211-1217.
Chabot D.J., Zhang P.F., Quinnan G.V., Broder C.C. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J. Virol. 1999, 73:6598-6609.
Mobius K., Durr R., Haussner C., Dietrich U., Eichler J. A functionally selective synthetic mimic of the HIV-1 co-receptor CXCR4. Chemistry 2012, 18:8292-8295.
Hashimoto C., Nomura W., Narumi T., Fujino M., Tsutsumi H., Haseyama M., Yamamoto N., Murakami T., Tamamura H. Anti-HIV-1 peptide derivatives based on the HIV-1 co-receptor CXCR4. ChemMedChem October 2013, 8(10):1668-1672.
Brelot A., Heveker N., Adema K., Hosie M.J., Willett B., Alizon M. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J. Virol. 1999, 73:2576-2586.
Dogo-Isonagie C., Lam S., Gustchina E., Acharya P., Yang Y., Shahzad-ul-Hussan S., Clore G.M., Kwong P.D., Bewley C.A. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. J. Biol. Chem. 2012, 287:15076-15086.
Cormier E.G., Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002, 76:8953-8957.
Brelot A., Heveker N., Pleskoff O., Sol N., Alizon M. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J. Virol. 1997, 71:4744-4751.
Reeves J.D., Heveker N., Brelot A., Alizon M., Clapham P.R., Picard L. The second extracellular loop of CXCR4 is involved in CD4-independent entry of human immunodeficiency virus type 2. J. Gen. Virol. 1998, 79(Pt 7):1793-1799.
Willett B.J., Adema K., Heveker N., Brelot A., Picard L., Alizon M., Turner J.D., Hoxie J.A., Peiper S., Neil J.C., Hosie M.J. The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. J. Virol. 1998, 72:6475-6481.
Arumugam K., Crouzy S., Chevigne A., Seguin-Devaux C., Schmit J.C. Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: validation through agonist and antagonist docking. J. Biomol. Struct. Dyn. 2013.
Drury L.J., Ziarek J.J., Gravel S., Veldkamp C.T., Takekoshi T., Hwang S.T., Heveker N., Volkman B.F., Dwinell M.B. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17655-17660.
Wang J., Shiozawa Y., Wang Y., Jung Y., Pienta K.J., Mehra R., Loberg R., Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283:4283-4294.
Gebauer F., Tachezy M., Effenberger K., von Loga K., Zander H., Marx A., Kaifi J.T., Sauter G., Izbicki J.R., Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J. Surg. Oncol. 2011, 104:140-145.
Zhong W., Chen W., Zhang D., Sun J., Li Y., Zhang J., Gao Y., Zhou W., Li S. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: a clinical study. Exp. Ther. Med. 2012, 4:363-369.
Veldkamp C.T., Seibert C., Peterson F.C., Sakmar T.P., Volkman B.F. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12). J. Mol. Biol. 2006, 359:1400-1409.
Secchi M., Longhi R., Vassena L., Sironi F., Grzesiek S., Lusso P., Vangelista L. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides. Chem. Biol. 2012, 19:1579-1588.
Lusso P., Vangelista L., Cimbro R., Secchi M., Sironi F., Longhi R., Faiella M., Maglio O., Pavone V. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 2011, 25:1230-1243.
